AlmouhawisHALeaoJCFedeleSPorterSR. Wegener’s granulomatosis: a review of clinical features and an update in diagnosis and treatment. J Oral Pathol Med. 2013;42:507-516.
2.
CabralDAUribeAGBenselerS. Classification, presentation, and initial treatment of Wegener’s granulomatosis in childhood. Arthritis Rheum. 2009;60:3413-3424.
3.
StoresundBGranJTKoldingsnesW. Severe intestinal involvement in Wegener’s granulomatosis: report of two cases and review of the literature. Br J Rheumatol. 1998;37:387-390.
4.
JayneDRasmussenNAndrassyK. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med. 2003;349:36-44.
5.
LangfordCATalar-WilliamsCSnellerMC. Use of methotrexate and glucocorticoids in the treatment of Wegener’s granulomatosis. Long-term renal outcome in patients with glomerulonephritis. Arthritis Rheum. 2000;43:1836-1840.
6.
De GrootKRasmussenNBaconPA. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2005;52:2461-2469.
7.
JonesRBFerraroAJChaudhryAN. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2009;60:2156-2168.
8.
StoneJHMerkelPASpieraR. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363:221-232.
9.
TwiltMBenselerSCabralD. Granulomatosis with polyangiitis in childhood. Curr Rheumatol Rep. 2012;14:107-115.
10.
BerdenAGoerogluAJayneD. Diagnosis and management of ANCA associated vasculitis. BMJ. 2012;344:e26.
